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PRECLINICAL STUDY
ependence of Platelet Thrombus Stability
n Sustained Glycoprotein IIb/IIIa Activation
hrough Adenosine 5=-Diphosphate Receptor
timulation and Cyclic Calcium Signaling
hinya Goto, MD,* Noriko Tamura, MS,* Hideyuki Ishida, MD,† Zaverio M. Ruggeri, MD‡
anagawa, Japan; and La Jolla, California
OBJECTIVES We sought to evaluate the mechanisms that support the stability of platelet aggregates on a
thrombogenic surface exposed to flowing blood.
BACKGROUND Activation of the membrane glycoprotein (GP) IIb/IIIa—mediated in part through the P2Y1
and P2Y12 adenosine 5=-diphosphate (ADP) receptors—is necessary for platelet aggregation.
Platelets in growing thrombi exhibit cyclic calcium signal, suggesting that sustained activation
may be required for thrombus stability.
METHODS Blood was perfused over type I collagen fibrils at the wall shear rate of 1,500 s1.
Three-dimensional visualization of platelet thrombi was obtained in real time with confocal
microscopy. The intracytoplasmic Ca2 concentration ([Ca2]i) was measured in fluo-3AM–
loaded platelets.
RESULTS The height of platelet thrombi in control blood was 13.5 3.3 m after 6 min, and increased
to 16.3  4.5 m (n  8) after an additional 6 min. In contrast, the height was reduced to
5.4  2.2 and 3.3  1.3 m, respectively (p  0.01, n  8), when the blood used in the
second 6-min perfusion contained a P2Y1 (MRS2179) or P2Y12 (AR-C69931MX) inhibitor.
The [Ca2]i of platelets within forming thrombi oscillated between 212 38 nmol/l and 924
 458 nmol/l, with cycles lasting 4.2  2.8 s that were inhibited completely by
AR-C69931MX and partially by MRS2179. Accordingly, thrombi became unstable upon
perfusion of blood containing the Ca2 channel blocker, lanthanum chloride. Flow
cytometric studies demonstrated that AR-C69931MX, MRS2179, and lanthanum chloride
reduced monoclonal antibody PAC-1 binding to platelets, indicating a decrease of
membrane-expressed activated GP IIb/IIIa.
CONCLUSIONS Continuous P2Y1 and P2Y12 stimulation resulting in cyclic [Ca
2]i oscillations is required for
maintaining the activation of GP IIb/IIIa needed for thrombus stability in flowing
blood. (J Am Coll Cardiol 2006;47:155–62) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.08.055Cardiology Foundation
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erterial thrombosis may initiate after the rupture of an
nstable atherosclerotic plaque, and it involves multiple
latelet adhesion and agonist receptors (1) as well as
ctivation of clotting with fibrin deposition (2,3). Two
denosine 5=-diphosphate (ADP) receptors, P2Y1 and
2Y12, mediate platelet stimulation induced not only by
xogenous ADP (4–6), but also by shear forces or interac-
ions with extracellular matrixes that cause ADP release
rom storage granules (7–9). In particular, P2Y12 concurs to
he stability of platelet aggregates (10) and may exert a
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ccepted August 1, 2005.imilar effect in developing arterial thrombi (11). In exper-
mental studies, platelets that adhere and aggregate onto
mmobilized von Willebrand factor (VWF) exhibit cyclic
scillations in intracytoplasmic Ca concentration
[Ca2]i) (12). These have been shown to depend on the
oncurrent function of P2Y12 and glycoprotein (GP) IIb/
IIa (integrin IIb3), and are linked to the recruitment and
ctivation of flowing platelets into growing thrombi (12).
uch findings, and the results obtained with a thrombosis
odel in P2Y12-deficient mice (13), suggest that continuing
timulation of ADP receptors may be required to initiate as
ell as propagate thrombus growth on damaged vascular
urfaces. Experiments with selective inhibitors have con-
rmed the importance of P2Y12 in this regard (12), while
2Y1 may be key for the initial activation of ADP-
timulated platelets (14) but have no role in thrombus
ropagation. In the present study, we have used a fibrillar
ype I collagen surface exposed to flowing blood and specific
ntagonists of the ADP receptors and GP IIb/IIIa to
valuate how aggregating platelets are incorporated irrevers-
bly into a thrombus. Our findings may contribute to
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gents.
ETHODS
lood samples. Venous blood was obtained from
edication-free volunteers (6 men, 2 women; age 28 to 43
ears) with their informed consent, and transferred into
lastic tubes containing 1/10 volume of the thrombin
nhibitor Argatroban (Mitsubishi Kagaku, Tokyo, Japan) to
ield a final concentration of 100 mol/l (15,16), which
oes not decrease the plasma divalent cation concentration.
latelet-rich plasma (PRP) was separated by centrifugation
t 100 g for 15 min and platelet-poor plasma (PPP) by
urther centrifugation at 800 g for 10 min. The platelet
ount in PRP was adjusted to 3  105/l.
eagents. AR-C69931MX (17) was from AstraZeneca
Loughborough, Leicestershire, United Kingdom). MRS2179
18) was obtained from Dr. Savi (Sanofi-Synthelabo Recher-
he, Toulouse, France). Lanthanum chloride (19), acid insol-
ble fibrillar collagen type I from bovine Achilles tendon,
igure 1. Three-dimensional projection imaging of platelet thrombi. A piez
o provide scanning images of the platelet thrombi (a’). The sum of the co
Abbreviations and Acronyms
ADP  adenosine diphosphate
[Ca2]i  intracytoplasmic Ca
2 concentration
FITC  fluorescein isothiocyanate
GP  glycoprotein
PPP  platelet-poor plasma
PRP  platelet-rich plasma
VWF  von Willebrand factorntervals relative to the x axis to obtain the three-dimensional projection images
B), and 90° (front view; C). The maximum height (h) of the platelet thrombiepacrine (quinacrine hydrochloride), acetyl salicylic acid,
DP, and epinephrine were from Sigma Chemical Co. (St.
ouis, Missouri). Tirofiban (Aggrastate) was from Merck &
o. (Allentown, Pennsylvania). Fluo-3 acetoxymethyl ester
Fluo-3AM) was from Molecular Probe (Eugene, Oregon).
easurement of thrombus volume. Platelets were ren-
ered fluorescent by adding 10 mol/l mepacrine (16,20) or
g/ml of the fluorescein isothiocyanate (FITC)-labeled
ab fragment of the anti-GP IIb/IIIa monoclonal antibody,
M337 (Yamanouchi Pharmaceutical Co. Ltd., Tokyo,
apan). Thrombi of similar size were obtained in either case
not shown). A rectangular flow chamber with type I
ollagen fibrils coated on the glass bottom (15,16,20) was
ssembled onto the stage of an inverted epifluorescence
icroscope (Leica, Germany). Blood was aspirated through
he chamber with a syringe pump (Harvard Apparatus,
olliston, Massachusetts) at a constant flow rate to yield a
all shear rate of 1,500 s1. Images were digitized on-line
ith a color CCD video camera (L-600, Leica, Germany).
hrombus growth was evaluated in two dimensions by
easuring the surface area covered by platelets (16) and in
hree dimensions by confocal microscopy (Fig. 1) as previ-
usly reported (15). The effect of inhibitors of platelet
unction on the stability of platelet thrombi was tested in
wo-stage experiments, consisting in the perfusion of un-
reated blood for 6 min followed by blood containing or not
test substance for an additional 6 min.
easurement of [Ca2]i. Platelets in PRP were incubated
or 30 min at 37°C with fluo-3AM (8 mol/l), then mixed
ith erythrocytes separated from the same blood and
ctric motor (a) moved the objective lens at a constant speed of 0.4 mol/l/s
l images in a bottom to top stack (z-axis) was projected on planes at 10°o-ele
nfocashown on the right, including projections at 0 degrees (top view; A), 60°
was calculated from the front view projection, as shown in C.
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January 3, 2006:155–62 ADP Receptors in the Stability of Platelet Thrombiashed three times by centrifugation and resuspension in a
uffer composed of 10 mmol/l HEPES, 140 mmol/l NaCl,
H 7.4 (HEPES buffer). The washed cells were resus-
ended in homologous PPP containing Argatroban (100
mol/l) at a 40% hematocrit. Unlike previously suggested
21) but in agreement with recent reports (22), we did not
se probenecid to prevent the leakage of fluo-3 because of
ts effects on platelet function (23). The [Ca2]i of 10
andomly selected platelets incorporated at different posi-
ions within a thrombus was measured using confocal
icroscopy. Variations in the fluorescence intensity of
uo-3AM were converted into [Ca2]i using the equation:
Ca2i  KdF  Fmin⁄Fmax  F
here Kd (495 nmol/l) is the dissociation constant of
uo-3AM for the interaction with Ca2 (21); F is the
easured fluorescent intensity of single platelets; Fmax is
he fluorescence intensity of single platelets treated with the
a2 ionophore A23187 (10 mol/l; Sigma) in the pres-
nce of 2 mmol/l Ca; and Fmin is the fluorescent
ntensity of unstimulated single platelets.
low cytometry. The platelet binding of FITC-conjugated
AC-1, a monoclonal antibody that selectively interacts
ith activated GP IIb/IIIa, was measured by flow cytometry
FACScan, Becton-Dickinson, San Jose, California). Plate-
ets in PRP were activated with the combination of ADP
nd epinephrine (25 mol/l each) or with the thrombin
eceptor activation peptide (1 mmol/l). Then, FITC-
onjugated PAC-1 was added at a final concentration of
.77 g/ml, followed by HEPES buffer containing or not
R-C69931MX (100 nmol/l), MRS2179 (100 mol/l), or
anthanum chloride (1 mmol/l). PAC-1 binding was mea-
ured 5, 10, 30, 45, and 60 min after addition of the last
igure 2. Three-dimensional projection images of thrombi formed in the
uoresceinated platelets was perfused over immobilized collagen type I fib
resence of MRS2179 (100 mol/l) or AR-C69931MX (100 nmol/l), as in
nd the resulting images were projected on planes rotated around the x-ax
ideos). The figure shows projection images from the top (A), 60° (B), and the
eparate experiments.olution. All these experiments were performed under static
onditions. The median fluorescence of 10,000 single plate-
ets was calculated using the CellQuest software (Becton
ickinson Biosciences).
tatistical analysis. All numerical data are expressed as
ean values  SD unless otherwise specified. The effect of
arious concentrations of AR-C69931MX and MRS2179
n the surface coverage by platelets was tested by one-way
nalysis of variance. Differences between two groups of data
ere compared by Newman-Keuls test. A p value of 0.05
as considered to denote statistical significance.
ESULTS
2Y1 and P2Y12 antagonists inhibit platelet thrombus
rowth. In agreement with previous results (7,8), ADP
eceptor antagonists inhibited thrombus growth on type I
ollagen fibrils exposed to blood flowing with a wall shear
ate of 1,500 s1. Platelet surface coverage decreased from
8.0  6.6% to 13.6  3.9% after blocking P2Y12 with 100
mol/l AR-C69931MX, and to 19.4  5.4% after blocking
2Y1 with 100 mol/l MRS2179 (p  0.01). Both antag-
nists also inhibited thrombus volume (Fig. 2). Untreated
lood perfused for 6 min formed multilayered thrombi with
height of 13.2  2.3 m (n  8), which was reduced to
single layer of platelets with a height of 3.2  1.1 m by
00 nmol/l AR-C69931MX (n  8). With blood contain-
ng 100 mol/l MRS2974, the thrombus height was 6.1 
.5 m (n  8), less than with untreated blood
p  0.01) but more than with the P2Y12 antagonist (p 
.01).
nhibitors of P2Y1, P2Y12, and Ca
2 channels reduce
latelet thrombus size. Blood perfused over collagen type
fibrils for 6 min at the wall shear rate of 1,500 s1 formed
ce or absence of adenosine diphosphate receptor antagonists. Blood with
or 6 min at the wall shear rate of 1,500 s1 in the absence (Control) or
d. The platelet thrombi were scanned in the z-axis by confocal microscopy,
10° intervals (please see the online version of this article for supplementalpresen
rils f
dicate
is atfront (C). These images are representative of the results obtained in eight
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ADP Receptors in the Stability of Platelet Thrombi January 3, 2006:155–62latelet thrombi with a height of 13.5  3.3 m (n  8;
ig. 3), increasing to 16.3  4.5 m after an additional 6
in. In contrast, when blood perfused in the second 6-min
eriod contained 100 nmol/l AR-C69931MX, thrombus
ize progressively decreased until a single layer of adherent
igure 3. Reduction in the size of platelet thrombi exposed to blood contain
s described in the caption of Figure 2, with the difference that the surface
epresentative images (0-degree and 90° projections) of platelet thrombi a
ee the online version of this article for supplemental videos). (B) Represen
before) or a second blood aliquot containing the P2Y12 inhibitor AR-C699
ideos). (C) Cross-sectional area occupied by fluorescent platelets in hori
ollagen surface, calculated as percentage of the area in the plane closest to
fter perfusion of untreated blood for 6 min. The bars labeled “No Additio
fter an additional 6 min perfusion of untreated blood, or blood treated w
RS2179 (100 mol/l), or the putative Ca2 channel inhibitor lanthanum
re shown.
igure 4. Changes in the two-dimensional and three-dimensional structu
xperiments were performed essentially as described in the caption of Fig
latelet thrombi immediately after perfusion of the first control blood aliqu
ntreated blood (No Addition) or blood containing tirofiban (0.5 mol/l), a
B) Cross-sectional area of thrombi at the indicated distances from the collagen s
erfusion for an additional 6 min of blood containing aspirin (100 mol/l) or tlatelets with a height of 3.3  1.3 m remained. A similar
ffect, resulting in a 3.4  1.2 m high single layer of
dherent platelets, was observed with the Ca2 channel
locker, lanthanum chloride (1 mmol/l), whereas 100
mol/l MRS2974 reduced thrombus height to 5.4  2.2
ifferent antagonists of platelet function. These experiments were performed
exposed to two subsequent aliquots of blood each perfused for 6 min. (A)
erfusion of the first (before) or second (after) control blood aliquot (please
images of platelet thrombi after perfusion of the first control blood aliquot
(100 nmol/l) (please see the online version of this article for supplemental
l planes passing through the thrombi at the indicated distance from the
gen surface. The bars labeled “Before” show the area of thrombi formed
R-C, MRS, and LAN show the area of thrombi remaining on the surface
he P2Y12 inhibitor AR-C69931MX (100 nmol/l), or the P2Y1 inhibitor
ide (LAN) (1 mmol/l), respectively. Mean and SEM of eight experiments
platelet thrombi exposed to blood containing antiplatelet agents. These
. (A) Representative two-dimensional fluorescence microscopy images of
min) or at different times after beginning the second perfusion with either
icated (please see the online version of this article for supplemental videos).ing d
was
fter p
tative
31MX
zonta
colla
n,” A
ith tre of
ure 3
ot (0
s indurface after perfusion of untreated blood for 6 min (No Addition), or after
irofiban (0.5 mol/l), as indicated. See Figure 3C for additional details.
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January 3, 2006:155–62 ADP Receptors in the Stability of Platelet Thrombim. The latter value was less than with untreated blood but
ore than with the anti-P2Y12 antagonist (n  8; p  0.01
or both comparisons; Fig. 3). Addition of 0.5 mol/l
irofiban, a GP II/IIIa antagonist (15), to the blood used in
he second perfusion also reduced thrombi to a single layer
f adherent platelets with a height of 3.1  1.1 m (n  8;
ig. 4), whereas 100 mol/l aspirin allowed continued
rowth to a height of 15.8  5.5 m (n  8; Fig. 4).
Platelets within thrombi exhibited cyclic [Ca2]i os-
illations (Fig. 5). The lowest average [Ca2]i was 212 
8 (SEM) nmol/l and the highest 924  458 nmol/l,
ith a cycle length from peak to peak of 4.2  2.8 s (Fig.
). These [Ca2]i variations appeared to depend on
pecific ion channels because they were blocked by the
a2 channel antagonist lanthanum chloride (not
hown). Addition of the P2Y12 antagonist to the perfused
lood rapidly decreased the platelet [Ca2]i within
ormed thrombi; after 2 min the value ranged between
82  22 nmol/l and 244  96 nmol/l without detectable
ycles in most platelets (Fig. 5). After addition of the P2Y1
ntagonist, the low and high [Ca2]i values ranged between
igure 5. Changes in the intracytoplasmic Ca2 concentration ([Ca2]i) o
xperiments were conducted as described in the caption of Figure 3, excep
latelets, washed erythrocytes, and homologous platelet-poor plasma with th
ell suspension was perfused over type I collagen fibrils at the shear rate o
ithout or with the addition of the P2Y12 antagonist AR-C69931MX (10
dditional 4 min. The [Ca2]i of platelets incorporated into thrombi wa
oncentration of five randomly selected platelets recorded for 10 s beginnin
he concentration of Ca2 ions in platelets within thrombi formed dur
R-C69931MX (ARC).92  34 nmol/l and 558  211 nmol/l, respectively, and bome but not all platelets showed measurable cycles of 5.8
.5 s (Fig. 5). Neither tirofiban, in spite of the pronounced
ffect on platelet thrombus size, nor aspirin had any influ-
nce on the cyclic [Ca2]i of aggregated platelets (not
hown).
nhibition of P2Y1 and P2Y12, and blockade of Ca
2
ntry reduce activated GP IIb/IIIa on platelets. Fluores-
ein isothiocyanate-conjugated PAC-1 binding to plate-
ets, measured as the median fluorescence intensity of
0,000 platelets, increased when platelets were activated
y the combination of ADP and epinephrine or the
hrombin receptor activating peptide (the results were
imilar and only the former are shown). Bound PAC-1
lowly but significantly decreased in time when no
dditional exogenous agonist was added after the initial
ctivation (Fig. 6). The reduction was more marked after
dding the P2Y12 inhibitor (Fig. 6), suggesting that
ontinuous stimulation is necessary to maintain the active
tate of GP IIb/IIIa. A similar effect was observed with
he P2Y1 inhibitor or the Ca
2 channel blocker (Fig. 7),
elet thrombi caused by adenosine diphosphate receptor antagonists. These
t blood was replaced with a cell suspension containing fluo-3AM–loaded
cific thrombin inhibitor argatroban (100 mol/l) as the anticoagulant. The
0 s1 for 4 min to form platelet thrombi. Then, the same cell suspension
l/l), or the P2Y1 antagonist MRS2179 (100 mol/l), was perfused for an
sured during the second perfusion. (Left panels) Intracytoplasmic Ca2
in after the start of the second perfusion. (Right panels) Images reflecting
erfusion of untreated blood (Control) or blood containing 100 nmol/lf plat
t tha
e spe
f 1,50
0 nmo
s mea
g 2 m
ing put not with aspirin (data not shown).
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ADP Receptors in the Stability of Platelet Thrombi January 3, 2006:155–62ISCUSSION
ur findings show that platelet thrombi growing on colla-
en may disperse several minutes after the initial aggrega-
ion when exposed to blood containing an ADP receptor
ntagonist or a putative Ca2 channel blocker or a GP
Ib/IIIa inhibitor. Thrombus stability, therefore, may de-
end on sustained ligand binding to activated GP IIb/IIIa,
hich in turn may be mediated by [Ca2]i elevations
nduced by the continuous stimulation of specific signaling
athways (Fig. 8). Our findings add to the concept of
ntercellular calcium communication, suggesting that it
perates bidirectionally from platelets at the growing edge
f a thrombus not only to activate newly recruited platelets
12) but also to ensure stability throughout the entire
ggregate. Such a conclusion is based on the observation
hat perfusion of blood containing ADP receptor antago-
ists reduced the cyclic [Ca2]i increases within platelet
hrombi even several minutes after the initial adhesive
ontacts had been established. Our experiments, however,
ould not define whether platelets at the center of thrombi
iffered in their Ca2 responses from those at the outer
dges. It has been proposed that cooperation between
2Y12-mediated activation and GP IIb/IIIa engagement by
igand promotes the activation of newly recruited platelets in
thrombus (12). We observed, however, that blocking GP
Ib/IIIa on the perfused platelets had no effect on the
Ca2]i oscillations within the thrombus even though it
aused progressive disaggregation. Thus, the effect of GP
Ib/IIIa inhibition on Ca2 signals may reflect the need of
aintaining newly recruited platelets in contact with adher-
igure 6. Changes in PAC-1 binding to activated platelets caused by
denosine diphosphate (ADP) receptor antagonists. To activate platelets,
5 l of HEPES buffer containing ADP and epinephrine (400 mol/l
ach) was mixed with 375 l of platelet-rich plasma and incubated for 20
in. Fifty l of fluorescein isothiocyanate-conjugated PAC-1 (25 g/ml)
as then added, and the fluorescence of individual platelets was measured
, 15, 30, 45, and 60 min after the addition of 50 l of HEPES buffer
ontaining or not the P2Y12 antagonist AR-C69931MX (100 nmol/l).
Upper panel) Mean and SEM of the median fluorescence of 10,000
latelets in eight experiments. (Lower panels) Representative flow cyto-
etric results at selected time points in one experiment without (solid
ines) or with (dotted lines) the addition of AR-C69931MX.nt ones until activation is induced. In the case of platelets
i
tlready aggregated into a thrombus, the replacement of an
dhesive ligand by a GP IIb/IIIa antagonist may result in
he detachment of platelets at the edge without effects on
he activation of those still in the thrombus.
We propose that cyclic [Ca2]i increases within platelet
hrombi reflect a mechanism that maintains GP IIb/IIIa
ctivation and, thus, thrombus stability. The experiments
ith lanthanum, a putative Ca2 channel blocker, support
uch a concept, but in this study we could not identify the
on channel involved or the signaling pathway regulating its
unction. Lanthanum, therefore, could have other effects,
uch as altering the ion binding sites of adhesive receptors
nd/or ligands (24) resulting in thrombus dissolution inde-
endently of Ca2 channel blocking. Moreover, the cyclic
Ca2]i increases of aggregated platelets within thrombi
ould be a consequence, not the cause of, maintaining GP
Ib/IIIa activation. In the alternative, the observation that
Ca2]i oscillations are linked to ADP receptor function
ay suggest an involvement of store-dependent Ca2 entry
25–27) mediated by P2Y12 simulation. From a technical
iewpoint, changes in platelet volume could have affected
he results obtained with fluo-3AM, a single-wave Ca2
ndicator, thus influencing our conclusions. It should be
oted that we have attempted to minimize such possible
ffects by using ultra-fast confocal microscopy, and no cyclic
latelet volume changes have been reported during throm-
us growth. In the end, sustained platelet activation neces-
ary for thrombus stability may involve various signaling
olecules, including ephrin/eph kinases (28), regulated by
igure 7. Effect of different platelet inhibitors on PAC-1 binding to
ctivated platelets. These experiments were performed as described in the
aption for Figure 6, with the only difference that the P2Y1 inhibitor,
RS2179, or the putative Ca2 channel blocker, lanthanum chloride, was
lso added to platelets after activation by adenosine diphosphate and
pinephrine. The upper panel shows the mean and SEM of the median
uorescence of 10,000 platelets measured 30 min after addition of
R-C69931MX (final concentration: 100 nmol/l), MRS2179 (final con-
entration: 100 mol/l), or lanthanum chloride (final concentration: 1
mol/l) as compared to control in which only buffer was added (n  8).
he lower panels show the actual flow cytometric results of one represen-
ative experiment. Solid lines represent the results in the presence of the
nhibitor shown in each panel, while dotted lines represent the results in
he absence of inhibition.
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January 3, 2006:155–62 ADP Receptors in the Stability of Platelet Thrombilatelet-platelet contacts at the upper edge of the growing
hrombus.
Although there is agreement that P2Y12 is involved in the
alcium signaling that sustains activation, conclusions on
he role of P2Y1 are not univocal, perhaps because previous
tudies were focused on the activation of newly recruited
latelets (12) while we analyzed the activation of platelets
lready incorporated within thrombi. The two processes
ay be distinct, or the discrepant results may be caused by
ethodological differences. For example, continuous rather
han periodic monitoring of [Ca2]i cycles may better reveal
he relatively weak effect of blocking P2Y1. Moreover,
thers have reported that only the combined blockade of
2Y1 and P2Y12 can inhibit platelet thrombus formation on
he surface of collagen (7), whereas we have shown previ-
usly (8) and confirm here that inhibition of either receptor
s almost equally effective in doing so. This discrepancy may
esult from differences in experimental observation times,
ecause we measured thrombus volume after several minutes
hen the stability may be more influenced by interplatelet
ommunication and less by the effects of the platelet-collagen
nteractions at the base of the thrombus.
Perhaps the main limitation of an ex vivo blood perfusion
odel is the need to use an anticoagulant to preserve blood
uidity, which in turn prevents the generation of thrombin
nd, consequently, of fibrin, both likely to have a role in
roviding thrombus stability (3,29). Nonetheless, ADP-
nduced signaling pathways may contribute to the overall
igure 8. Schematic representation of the mechanism that stabilizes plat
irculating platelets adhere and become activated onto collagen through m
illebrand factor (VWF) under high shear rate conditions. Full activation
oluble adhesive ligands such as VWF and fibrinogen. These form the new
hear rate conditions by GP Ib-VWF binding. Adhesive interactions and
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